Kyowa Kirin Korea Co., Ltd.
基本情報
- 所在地
- 社長
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 終了日
サイト
事業内容
関連会社
関連図
沿革
Dr. Shibasaburo Kitasato and Dr. Bering discovered that the serum obtained from an animal infected with diphtheria was effective in the treatment of diphtheria and tetanus; they established serum therapy.![]()
Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.![]()
Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).![]()
Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first).![]()
Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.![]()
César Milstein, Georges Köhler and Niels Kaj Jerne established the hybridoma technology, which is a technology for producing monoclonal antibodies.![]()
The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.![]()
Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).![]()
Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.![]()
The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug.![]()
Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.![]()
ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.![]()
Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan.![]()
Crysvita® approved in the US and Europe for X-linked hypophosphatemia. Poteligeo® approved in the US and Europe for mycosis fungoides (MF) and Sézary syndrome (SS).![]()
Trade name changed to Kyowa Kirin Co., Ltd. Crysvita® launched in Japan for FGF23-related Hypophosphatemic Rickets and Osteomalacia. Nourianz™ launched in the US for Parkinson's disease.![]()
Poteligeo® launched in Europe for mycosis fungoides (MF) and Sézary syndrome (SS). Crysvita® approved in the US for tumor-induced osteomalacia (TIO).![]()
Global DE&I Statement adopted. Launch of G-Lasta® Subcutaneous Injection 3.6 mg BodyPod. Completion of Q-TOWER analysis facility.![]()
ニュース
ニュースはありません。